

Newsletter

Issue No. 42

August 2022 Edition **HIV Trainee Association newsletter**

We hope that you enjoyed the excellent presentations from our last workshop; 'Antiretroviral therapy and DipHIV revision' in April 2022.

Below is a summary of the topics covered from our last workshop. You can watch the recordings of the workshop on our website by clicking the following link: . <https://hivta.org.uk/members-content-categories/videos/>

- Antiretrovirals in the first 35 years, Ms Emma Wrench
- Presenting with impact, Dr Naomi Sutton
- Syphilis for DipHIV, Dr Harriet Wallace
- PREP, Dr Gary Whitlock
- National HIV ART Prescribing Toolkit, Dr Steve Taylor
- New ARVs & the future of HIV Treatment & prevention, Professor Chloe Orkin

SAVE THE DATE!

Our next workshop is planned on Thursday 24th November 2022 to coincide with the Autumn BHIVA conference on 25th November 2022, so please save the date. We always welcome suggestions for future topics in our workshop. So please do email us if you have any suggestion.

The workshop will be held at The Little Ship Club, Three Cranes Walk, London, EC4R 3TB. An agenda will be coming soon!

As always, we give great thanks to our sponsors, Gilead and ViiV for their continued support.

We would like to welcome some new committee members including Manik Kohli, Alice Parsloe, Amelia Benjamin and Fiona Windebank. I would also like to thank our demitting committee members, including Johanna Denman, Khine Phyu, Matthew Page and Michael Ewens for their hard work and contributions in setting direction for, and the rebranding of the association.

Finally, on behalf of the committee, would like to express our gratitude for your continued support at our events. We look forward to seeing everyone in November.

Yee Suh Teh
Editor

Message from the Chair...

I would like to say a huge thank you for the hard work, time and patience our committee and members have had during our rebrand, as we learn to become a more hybrid association. As you can see from our website, which launched last year, our interactive members' area now includes a video recording and PDFs of talks given at our workshops. This has enabled people who have not been able to attend in person, due to the COVID-19 pandemic, access to our resources. This would not be possible without our sound and filming crew, and the support of Gilead & Viiv.

Now that my tenure is over as Chair, I would like to pay special thanks to past and present committee members. I wish all of those who have completed training the best of luck with their Consultant jobs. We have now got IMT committee members to help increase recruitment to the speciality, and recognise the change in training for GUM trainees. It is important to note that the HIVTA is open to anyone in IMT, GUM, ID or Microbiology training. If you are not sure if you can join a workshop - drop our Secretariat, Fiona, a quick line at info@HIVTA.org.uk

Wishing everyone a healthy start to their new training year, all the best,

Mikey Ewens
Demitting Chair

For more information, please refer to our website <https://hivta.org.uk>
Please send any comments/views to: info@hivta.org.uk
Twitter: @hivta_uk

STASHH
Student & Trainee Association
for Sexual Health and HIV

What do we do?

- Projects**
Audit, QIP, research and clinical shadowing opportunity database
- Mentoring**
Careers counselling and personal & professional development
- Careers**
Hosting and signposting careers events
- Education**
Monthly webinars

Follow us:

- STASHH UK**
- @STASHH_UK**
- stashh@bashh.org**

Committee Steering Group 2022

Michael Ewens	Chair (Demitting)
Matthew Page	Vice-Chair (Demitting)
Alice Parsloe	Incoming Chair
Jozef Shaw	Finance/Sponsorship
Amelia Benjamin	Finance/Sponsorship
Cristina Fernandez	Research Offiicer
Alex Langrish	Education Officer
Yee Suh Teh	Social Media/Newsletter
Fiona Windebank	Education Officer
Manik Kohli	Education Officer

Upcoming Events 2022

November

HIVTA Workshop

24th November – London

BHIVA Autumn Conference

25th November - London



BIKTARVY[®] ▼
bictegravir 50mg/emtricitabine 200mg/
tenofovir alafenamide 25mg tablets



Building confidence together

UK data from a long-running HIV real time sample study* shows that, from January to December 2021, **Biktarvy was the number one naïve product prescribed by participating doctors.**^{1*}

The same study shows that, from January to December 2021, for participating doctors, Biktarvy was one of the top preferred switch options, and that 72% of patients prescribed Biktarvy were switched over from a non-TAF regimen.^{2†}

Biktarvy is indicated for the treatment of adults infected with human immunodeficiency virus-1 (HIV-1) without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir.^{3,4}

For healthcare professionals only

This study is a syndicated report, with no influence on design from Gilead, nor is it using a Gilead (or any other manufacturer) target list to recruit physicians.^{1,2}

* This includes 1,168 patients naïve to ART, across 12 months (January-December 2021).¹ 47 doctors reporting on 1,168 initiating patients in the UK.¹ Use of Biktarvy as a regimen for all initiating patients from January to December 2021 was 25%.¹

† This study includes 1,169 existing ART patients who switched during these 12 months.² 47 doctors reporting on 1,169 HIV patients switching to a new regimen at the time of visit in the UK.² Use of Biktarvy as a regimen among all switching patients from January to December 2021 was 17%.²

References:

1. Data on file (naïve), Gilead Sciences, January 2022.
2. Data on file (switch), Gilead Sciences, January 2022.
3. Biktarvy Summary of Product Characteristics (England, Scotland and Wales).
4. Biktarvy Summary of Product Characteristics (Ireland and Northern Ireland).

This is a stock image and not a person living with HIV
ART, Anti-retroviral therapy; HIV, Human immunodeficiency virus;
TAF, tenofovir alafenamide.

UK-BVY-0700 June 2022

[Click here](#) for Biktarvy prescribing information (England, Scotland and Wales)

[Click here](#) for Biktarvy prescribing information (Ireland and Northern Ireland)

Adverse events should be reported. For Great Britain and Northern Ireland, reporting forms and information can be found at www.mhra.gov.uk/yellowcard/ or via the Yellow Card app (download from the Apple App Store or Google Play Store). Adverse events should be reported to Gilead (safety_FC@gilead.com) or +44 (0) 1223 897500.

Adverse events should be reported. For Ireland, reporting forms and information can be found at www.hpra.ie and can be reported to HPRA on +353 1 6764971. Adverse events should also be reported to Gilead (safety_FC@gilead.com) or +44 (0) 1223 897500